Skip to main content

Advertisement

SpringerLink
Log in

Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN).

Methods

This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined.

Results

There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications.

Conclusion

A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413–24.

    CAS  PubMed  Google Scholar 

  2. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 2006;70:1403–12.

    Article  CAS  PubMed  Google Scholar 

  3. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol. 1995;34:866–72.

    Article  CAS  PubMed  Google Scholar 

  4. Niaudet P. Treatment of lupus nephritis in children. Pediatr Nephrol. 2000;14:158–66.

    Article  CAS  PubMed  Google Scholar 

  5. Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol. 1996;7:924–9.

    CAS  PubMed  Google Scholar 

  6. Cameron JS. Lupus nephritis in childhood and adolescence. Pediatr Nephrol. 1994;8:230–49.

    Article  CAS  PubMed  Google Scholar 

  7. Adams A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs. 2006;66:1191–207.

    Article  CAS  PubMed  Google Scholar 

  8. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.

    Article  CAS  PubMed  Google Scholar 

  9. Filler G, Buffo I. Safety considerations with mycophenolate sodium. Expert Opin Drug Saf. 2007;6:445–9.

    Article  CAS  PubMed  Google Scholar 

  10. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19:703–10.

    Article  CAS  PubMed  Google Scholar 

  11. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int. 2000;58:51–61.

    Article  CAS  PubMed  Google Scholar 

  12. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. New Engl J Med. 2000;343:1156–62.

    Article  CAS  PubMed  Google Scholar 

  13. Chan TM, Tse KC, Tang CS, Mok MY, Li FK, Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076–84.

    Article  CAS  PubMed  Google Scholar 

  14. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New Engl J Med. 2005;353:2219–28.

    Article  CAS  PubMed  Google Scholar 

  15. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38:69–78.

    Article  CAS  PubMed  Google Scholar 

  17. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007;2:968–75.

    Article  CAS  PubMed  Google Scholar 

  18. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol. 2001;28:2103–8.

    CAS  PubMed  Google Scholar 

  19. Falcini F, Capannini S, Martini G, La Torre F, Vitale A, Mangiantini F, et al. Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus. 2009;18:139–43.

    Article  CAS  PubMed  Google Scholar 

  20. Kazyra I, Pilkington C, Marks SD, Tullus K. Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child. 2010;95:1059–61.

    Article  PubMed  Google Scholar 

  21. Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005;19:199–206.

    Article  PubMed  Google Scholar 

  22. Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231–6.

    Article  CAS  PubMed  Google Scholar 

  23. Sollinger H. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc. 2004;36:517S–20S.

    Article  CAS  PubMed  Google Scholar 

  24. Burg M, Saemann MD, Wieser C, Kramer S, Fischer W, Lhotta K. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients. Transplant Proc. 2009;41:4159–64.

    Article  CAS  PubMed  Google Scholar 

  25. Calvo N, Sanchez-Fructuoso AI, Conesa J, Moreno A, Barrientos A. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transplant Proc. 2006;38:2396–7.

    Article  CAS  PubMed  Google Scholar 

  26. Meneses Rde P, Kotsifas CH. Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function. Pediatr Transplant. 2009;13:188–93.

    Article  PubMed  Google Scholar 

  27. Traitanon O, Avihingsanon Y, Kittikovit V, Townamchai N, Kanjanabuch T, Praditpornsilpa K, et al. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus. 2008;17:744–51.

    Article  CAS  PubMed  Google Scholar 

  28. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.

    Article  CAS  PubMed  Google Scholar 

  29. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549–57.

    Article  CAS  PubMed  Google Scholar 

  30. Weng MY, Weng CT, Liu MF. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol. 2010;29:771–5.

    Article  PubMed  Google Scholar 

  31. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259–63.

    CAS  PubMed  Google Scholar 

  32. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function–measured and estimated glomerular filtration rate. New Engl J Med. 2006;354:2473–83.

    Article  CAS  PubMed  Google Scholar 

  33. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–50.

    Article  PubMed  Google Scholar 

  34. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012;27:3248–54.

    Article  PubMed  Google Scholar 

  35. Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010;62:873–80.

    Article  PubMed  Google Scholar 

  36. Kitiyakara C, Ophascharoensuk V, Changsirikulchai S, Ingsathit A, Tankee P, Sangpanich A, et al. Treatment of lupus nephritis and primary glomerulonephritis with enteric-coated mycophenolate sodium. Clin Nephrol. 2008;69:90–101.

    Article  CAS  PubMed  Google Scholar 

  37. Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20:1484–93.

    Article  CAS  PubMed  Google Scholar 

  38. Navaneethan SD, Viswanathan G, Strippoli GF. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence. Drugs. 2008;68:2095–104.

    Article  CAS  PubMed  Google Scholar 

  39. Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61:74–87.

    Article  PubMed  Google Scholar 

  40. Yong PF, D’Cruz DP. Mycophenolate mofetil in the treatment of lupus nephritis. Biologics. 2008;2:297–310.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Hogan J, Schwenk MH, Radhakrishnan J. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Kidney Int. 2012;82:1256–60.

    Article  CAS  PubMed  Google Scholar 

  42. Paredes A. Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? Pediatr Nephrol. 2007;22:1077–82.

    Article  PubMed  Google Scholar 

  43. Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, et al. Lupus nephritis: induction therapy in severe lupus nephritis—should MMF be considered the drug of choice? Clin J Am Soc Nephrol. 2013;8:147–53.

    Article  PubMed  Google Scholar 

  45. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford). 2009;48:944–52.

    Article  CAS  Google Scholar 

  46. Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22:1933–42.

    Article  CAS  PubMed  Google Scholar 

  47. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64:375–83.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan, ROC

    Hsin-Hsu Chou

  2. Department of Long Term Care, Chung Hwa University of Medical Technology, Tainan, Taiwan, ROC

    Mei-Ju Chen

  3. Department of Pediatrics, National Cheng-Kung University Hospital, College of Medicine, Tainan, Taiwan, ROC

    Yuan-Yow Chiou

  4. Institute of Clinical Medicine, National Cheng-Kung University Hospital, College of Medicine, 138 Sheng-Li Rd., Tainan, Taiwan, ROC

    Yuan-Yow Chiou

Authors
  1. Hsin-Hsu Chou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mei-Ju Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuan-Yow Chiou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuan-Yow Chiou.

Ethics declarations

Conflict of interest

The authors have declared that no Conflict of interest exists.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chou, HH., Chen, MJ. & Chiou, YY. Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study. Clin Exp Nephrol 20, 628–636 (2016). https://doi.org/10.1007/s10157-015-1171-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-015-1171-6

Keywords

Search

Navigation